
**Claims**

1. A compound of Formula III, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof:

$$A^1\text{-}L^1\text{-}B^1 \qquad \text{III}$$

wherein:

$A^1$ is of Formula IA:



IA

wherein:

Y is a bond, $-CH_2-$, or $-CH_2-CH_2-$;

Z is a bond or O;

$R^1$, $R^2$, $R^3$, and $R^4$ are each independently hydrogen, halo, cyano, nitro, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, $C_{2-12}$ alkynyl, $C_{3-10}$ cycloalkyl, heterocyclyl, aryl, heteroaryl, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-OC(=O)R^{15}$, $-C(=O)NR^{15}R^{16}$, $-NR^{15}C(=O)R^{16}$, $-NR^{15}C(=O)OR^{16}$, $-S(=O)_{1-2}R^{15}$, $-S(=O)_{1-2}NR^{15}R^{16}$, $-NR^{15}S(=O)_{1-2}R^{16}$, $-Si(R^{15})_3$, or $-C=NOR^{15}$, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of $R^1$, $R^2$, $R^3$, and $R^4$ are independently optionally substituted with one or more $R^{10}$ as valency permits;

or $R^1$ and $R^2$ are taken together with the atoms to which they are attached to form a $C_{3-10}$ cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with one or more $R^{10}$ as valency permits;

or $R^2$ and $R^3$ are taken together with the atoms to which they are attached to form a $C_{3-10}$ cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with one or more $R^{10}$ as valency permits;

or $R^3$ and $R^4$ are taken together with the atoms to which they are attached to form a $C_{3-10}$ cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with one or more $R^{10}$ as valency permits;


each $R^{10}$ is independently halo, cyano, nitro, $-OR^{17}$, $-SR^{17}$, $-SF_5$, $-NR^{17}R^{18}$, $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, $C_{2-12}$ alkynyl, $C_{3-10}$ cycloalkyl, heterocyclyl, aryl, heteroaryl, $-C(=O)R^{17}$, $-C(=O)OR^{17}$, $-OC(=O)OR^{17}$, $-OC(=O)R^{17}$, $-C(=O)NR^{17}R^{18}$, $-OC(=O)NR^{17}R^{18}$, $-NR^{7}C(=O)NR^{17}R^{18}$, $-S(=O)_{1-2}R^{17}$, $-S(=O)_{1-2}NR^{17}R^{18}$, $-NR^{17}S(=O)_{1-2}R^{18}$, $-NR^{17}S(=O)_{1-2}NR^{17}R^{18}$, $-NR^{17}C(=O)R^{18}$, $-NR^{17}C(=O)OR^{18}$, $-Si(R^{17})_3$, or $-C=NOR^{17}$, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl of $R^{10}$ are independently optionally substituted with one or more halo or $C_{1-12}$ alkyl optionally substituted by oxo, halo, hydroxyl, or amino as valency permits; and


each $R^{15}$ and $R^{16}$ is independently hydrogen, $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, $C_{2-12}$ alkynyl, or $C_{3-12}$ cycloalkyl, wherein each alkyl, alkenyl, alkynyl, or cycloalkyl is optionally independently substituted with oxo, halo, hydroxyl, or amino as valency permits; or $R^{15}$ and $R^{16}$ are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or $C_{1-12}$ alkyl optionally substituted by oxo, halo, hydroxyl, or amino; and


each $R^{17}$ and $R^{18}$ is independently hydrogen, $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, $C_{2-12}$ alkynyl, or $C_{3-12}$ cycloalkyl, wherein each $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, $C_{2-12}$ alkynyl, or $C_{3-12}$ cycloalkyl is optionally substituted with oxo, halo, hydroxyl, or amino as valency permits; or $R^{17}$ and $R^{18}$ are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or $C_{1-12}$ alkyl optionally substituted by oxo, halo, hydroxyl, or amino;


wherein one or more atoms in one of $R^1$, $R^2$, and $R^3$ of Formula IA is replaced by a direct covalent bond to $L^1$;


$B^1$ is a nuclear receptor-targeting epitope selected from the group consisting of:




,


,


,


,



, and



, wherein the wavy bond refers to the point of connection to $L^1$; and

$L^1$ is a covalent bond or a linking moiety.

2. The compound of claim 1, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof wherein $A^1$ is of Formula IB:



IB

wherein:

$R^1$ is hydrogen, -C=NOR$^{15}$, or $C_{1-6}$ alkyl optionally substituted with one or more $R^{10}$ ;

$R^2$ is hydrogen, $C_{1-6}$ alkyl, -NR$^{17}$R$^{18}$, -$NO_2$, -$C_{1-6}$ alkylene-O-$C_{1-6}$ alkyl, or -$C_{1-6}$ alkylene-NR$^{17}$R$^{18}$; or

$R^1$ and $R^2$ are taken together with the atoms to which they are attached to form a $C_{3-10}$ cycloalkyl optionally substituted with one or more $R^{10}$;

$R^3$ is hydrogen, hydroxy, halo, $C_{1-6}$ alkyl, or -O-$C_{1-6}$ alkyl;

$R^4$ is hydrogen, halo, $C_{1-6}$ alkyl, or -O-$C_{1-6}$ alkyl; or


$R^3$ and $R^4$ together form a -O-$CH_2$-O- or -O-$CH_2CH_2$-O-;

Y is a bond, -$CH_2$-, or -$CH_2$-$CH_2$-; and

Z is a bond or O;

wherein one or more atoms in one of $R^1$, $R^2$, and $R^3$ is replaced by a direct covalent bond to $L^1$.

3. The compound of claim 1, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (ID):




(ID),

wherein:

$R^4$ is hydrogen, halo, methyl, or methoxy; and

each of $R^{17}$ and $R^{18}$ is independently hydrogen, $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, or $C_{2-12}$ alkynyl, wherein each $C_{1-12}$ alkyl, $C_{2-12}$ alkenyl, or $C_{2-12}$ alkynyl is optionally substituted with oxo, halo, hydroxyl, or amino as valency permits; or $R^{17}$ and $R^{18}$ are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or $C_{1-12}$ alkyl optionally substituted by oxo, halo, hydroxyl, or amino.


4. The compound of claim 1, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IF):



(IF),

wherein $R^4$ is hydrogen, halo, methyl, or methoxy.











5. The compound of claim 1, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IK):



(IK).




6. The compound of any one of claims 1-4, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein Y is -$CH_2$- and Z is O.


7. The compound of claim 1, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein $A^1$ is:

, or

8. The compound of claim 1, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein $A^1$ is:




, or


, wherein the wavy bond refers to the point of connection to $L^1$.

9. The compound of any one of claims 1-8, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein $L^1$ is of formula:

$$-(L^a)_q-,$$

wherein:

each $L^a$ is independently $-NR^{110}-$, $-O-$, $-S(O)_{0-2}-$, $-NR^{110}C(O)-$, $-C(O)NR^{110}-$, $-NR^{110}C(O)NR^{110}-$, $-NR^{110}S(O)_2-$, $-S(O)_2NR^{110}-$, $-NR^{110}S(O)_2NR^{110}-$, $-CR^{120}=N-NR^{110}-$, $-NR^{110}-N=CR^{120}-$, $-C(O)-$, $-OC(O)-$, $-OC(O)O-$, $-C(O)O-$, alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, or heteroarylene, wherein each alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, or heteroarylene is independently optionally substituted with one to five substituents independently selected from the group consisting of oxo, halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy, aryl, heteroaryl, cycloalkyl, and heterocyclyl;

each $R^{110}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;

each $R^{120}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl; and

q is an integer from 0 to 20.

10. The compound of any one of claims 1-9, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein $L^1$ is of the formula:

$$-Y^{10}-(CHR^{130})_{n'}-Y^{20}-(CHR^{140})_{n''}-Y^{30}-(CHR^{150})_{m''}-Y^{40}-$$

wherein:

each of $Y^{10}$, $Y^{20}$, $Y^{30}$, and $Y^{40}$ are independently a bond, -$NR^{110}$-, -O-, -$S(O)_{0-2}$-, -$NR^{110}C(O)$-, -$C(O)NR^{110}$-, -$NR^{110}C(O)NR^{110}$-, -$NR^{110}S(O)_2$-, -$S(O)_2NR^{110}$-, -$NR^{110}S(O)_2NR^{110}$-, -$CR^{120}$=N-$NR^{110}$-, -$NR^{110}$-N=$CR^{120}$-, -C(O)-, -OC(O)-, -OC(O)O-, -$(CH_2CH_2O)_{1-5}$-, -C(O)O-, alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, and heteroarylene; wherein each alkylene, alkenylene, alkynylene, arylene, cycloalkylene, heterocyclylene, or heteroarylene is independently optionally substituted with one to five substituents independently selected from the group consisting of oxo, halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, and $C_{1-4}$ haloalkoxy;

each $R^{110}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;

each $R^{120}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;

each $R^{130}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;

each $R^{140}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl;

each $R^{150}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $C_{1-4}$ alkoxy, $C_{1-4}$ haloalkoxy aryl, heteroaryl, cycloalkyl, or heterocyclyl; and

n', n'', and m'' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

11. The compound of any one of claims 1-9, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein $L^1$ is of the formula:

$$-Y^{10}-(CH_2)_{n'}-Y^{20}-(CH_2)_{p'}-Y^{30}-$$


wherein each of $Y^{10}$, $Y^{20}$, and $Y^{30}$ are independently a bond, optionally substituted alkylene, optionally substituted heteroalkylene, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted cycloalkylene, optionally substituted heterocyclylene, -$CR^{110}R^{120}$-, -$NR^{110}$-, -O-, -$S(O)_{0-2}$-, -$NR^{110}C(O)$-, -$C(O)NR^{110}$-, -$NR^{110}S(O)_2$-, -$S(O)_2NR^{110}$-, -$CR^{120}$=N-$NR^{110}$-, -$NR^{110}$-N=$CR^{120}$-, -OC(O)-, or -C(O)-;


each $R^{110}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;















each $R^{120}$ is independently hydrogen, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and









n' and p' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.


12. The compound of any one of claims 1-9, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein the linking moiety is of the formula:






















wherein the “*”and the wavy or dashed line each represent a covalent bond.

13. A compound selected from the group consisting of:







,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,




,



,




, and




or a pharmaceutically acceptable salt thereof.

14. The compound of claim 13, wherein the compound is:




or a pharmaceutically acceptable salt thereof.

15. The compound of claim 13, wherein the compound is




16. The compound of claim 13, wherein the compound is:




or a pharmaceutically acceptable salt thereof.

17. The compound of claim 13, wherein the compound is:




18. The compound of claim 13, wherein the compound is:




or a pharmaceutically acceptable salt thereof.

19. The compound of claim 13, wherein the compound is:



.


20. The compound of claim 13, wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

21. The compound of claim 13, wherein the compound is:



.


22. The compound of claim 13, wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

23. The compound of claim 13, wherein the compound is:



.


24. The compound of claim 13, wherein the compound is:



,


or a pharmaceutically acceptable salt thereof.

25. The compound of claim 13, wherein the compound is:



.


26. The compound of claim 13, wherein the compound is:




,

or a pharmaceutically acceptable salt thereof.

27. The compound of claim 13, wherein the compound is:




28. The compound of claim 13, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

29. The compound of claim 13, wherein the compound is:



30. A pharmaceutical composition comprising a compound of any one of claims 1-29, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

31. Use of the compound of any one of claims 1-29, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 30 in the manufacture of a medicament for treating cancer.

32. The use of claim 31, wherein the cancer is liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphomas, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia,

Waldenström macroglobulinemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, trophoblastic neoplasms, or prostatic carcinoma.

33. The use of claim 31 or 32, wherein the cancer is a breast, prostate, or ovarian cancer.